In This Article:
Three abstracts accepted for poster presentations on ALG-000184 and ALG-055009
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced four abstracts have been accepted, including one late-breaker oral presentation and three poster presentations, at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting (TLM) 2024, being held November 15 – 19, 2024 in San Diego, CA. The abstracts released today can be found on the AASLD website at https://www.aasld.org/the-liver-meeting. Late-breaker abstracts will be available on November 15, 2024.
Details on the abstracts are as follows:
ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B (CHB)
Abstract #: 1213
Title: Monotherapy with the Capsid Assembly Modulator, ALG-000184, Results in High Viral Suppression Rates in Untreated HBeAg+ and HBeAg- Subjects with Chronic Hepatitis B or Chronic Hepatitis B Virus Infection
Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
Date/Time: November 15, 2024, 8:00am – 5:00pm PT
Abstract #: 1266
Title: Capsid Assembly Modulators Such as ALG-001075 Induce Profound HBV DNA Knockdown and Directly Target HBeAg In Vitro
Presenter: Cheng Liu, PhD
Date/Time: November 15, 2024, 8:00am – 5:00pm PT
ALG-055009: Potential best-in-class small molecule THR-β for Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Format: Oral presentation
Title: ALG-055009, a Novel Thyroid Hormone Receptor Beta (THR-β) Agonist, was Well-tolerated with Significant Reductions in Liver Fat at Week 12 in Non-cirrhotic MASH Patients in the Ongoing Randomized, Double-Blind, Placebo-controlled Phase 2
Presenter: Rohit Loomba, MD, MHSc, Chief, Division of Gastroenterology and Hepatology, University of California, San Diego
Date/Time: November 19, 2024 at 10:30am – 10:40am PT
Abstract #: 3226
Title: Nonclinical Toxicology Profile of ALG-055009, a Novel and Potent Thyroid Hormone Receptor β Agonist, for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Presenter: Dinah Misner, PhD
Date/Time: November 17, 2024, 8:00am – 5:00pm PT
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) and viruses with high unmet medical need such as hepatitis B and coronaviruses.